Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer

참고문헌 (202)

1. Ochoa, D., "Open targets platform : supporting systematic drug-target identification and prioritisation", Nucleic Acids Res, 49, pp.D1302~D1310 (2021)
2. Koscielny, G., "Open targets : a platform for therapeutic target identification and validation", Nucleic Acids Res, 45, pp.D985~D994 (2017)
3. Carvalho-Silva, D., "Open targets platform : new developments and updates two years on", Nucleic Acids Res, 47, pp.D1056~D1065 (2019)
4. Snel, B., "STRING : a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene", Nucleic Acids Res, 28, pp.3442~3444 (2000)
5. von Mering, C., "STRING : a database of predicted functional associations between proteins", Nucleic Acids Res, 31, pp.258~261 (2003)
6. Szklarczyk, D., "The STRING database in 2011 : functional interaction net works of proteins, globally integrated and scored", Nucleic Acids Res, 39, pp.D561~D568 (2011)
7. Szklarczyk, D., "The STRING database in 2017 : quality-controlled protein protein association networks, made broadly accessible", Nucleic Acids Res, 45, pp.D362~D368 (2017)
8. Szklarczyk, D., "The STRING database in 2023 : protein-protein association networks and functional enrichment analyses for any sequenced genome of interest", Nucleic Acids Res, 51, pp.D638~D646 (2023)
9. Szklarczyk, D., "The STRING database in 2021 : customizable protein-protein networks, and functional characterization of user-uploaded gene", measurement sets, 2021, pp.49, D605~D612
10. Bussink, A. P., "Evolution of mammalian chitinase(-like)members of family 18 glycosyl hydrolases", Genetics, 177, pp.959~970 (2007)
11. Boot, R. G., "Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages", J. Biol. Chem, 270, pp.26252~26256 (1995)
12. Bonneh-Barkay, D., "Astrocyte and macrophage regulation of YKL-40expression and cellular response in neuroinflammation", Brain Pathol, 22, pp.530~546 (2012)
13. Hakala, B. E., "Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family", J. Biol. Chem, 268, pp.25803~25810 (1993)
14. Henrissat, B., "A classification of glycosyl hydrolases based on amino acid sequence similarities", Biochem. J, 280, pp.309~316 (1991)
15. Kognole, A. A., "Inhibition of Mammalian Glycoprotein YKL-40 : IDENTIFICATION OF THE PHYSIOLOGICAL LIGAND", J. Biol. Chem, 292, pp.2624~2636 (2017)
16. Volck, B., "YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils", Proc. Assoc. Am. Phys, 110, pp.351~360 (1998)
17. Rehli, M., "Molecular characterization of the gene for human cartilage gp-39(CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation", Genomics, 43, pp.221~225 (1997)
18. Hinsinger, G., "Chitinase 3-like proteins as diagnostic and prognostic bio markers of multiple sclerosis", Mult. Scler, 21, pp.1251~1261 (2015)
19. Francescone, R. A., "Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma", J. Biol. Chem, 286, pp.15332~15343 (2011)
20. Faibish, M., "A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression : a potential therapeutic agent in cancers", Mol. Cancer Ther, 10, pp.742~751 (2011)
21. Eurich, K., "Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells", World J. Gastroenterol, 15, pp.5249~5259 (2009)
22. Rathcke, C. N., "YKL-40, a new inflammatory marker with rela tion to insulin resistance and with a role in endothelial dysfunction and atherosclerosis", Inflamm. Res, 55, pp.221~227 (2006)
23. Quintana, E., "Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neuro f ilament light chain", Eur. J. Neurol, 25, pp.1189~1191 (2018)
24. Querol-Vilaseca, M., "YKL-40(Chitinase 3-like I)is expressed in a subset of astrocytes in Alzheimer’s disease and other tauopathies", J. Neuroinflamm, 14, pp.118~ (2017)
25. Kumagai, E., "Serum YKL-40 as a marker of liver fibrosis in patients with non alcoholic fatty liver disease", Sci. Rep, 6, pp.35282~ (2016)
26. Di Rosa, M., "Expression of CHI3L1 and CHIT1 in osteoarthritic rat cartilage model. A mor phological study", Eur. J. Histochem, 58, pp.2423~ (2014)
27. Di Rosa, M., "Chitinase 3 Like-1 : an emerging molecule involved in diabetes and diabetic complications", Pathobiology, 83, pp.228~242 (2016)
28. He, C. H., "Chitinase 3-like 1 regulates cellular and tissue responses via IL-13receptor alpha2", Cell Rep, 4, pp.830~841 (2013)
29. Subramaniam, R., "Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer", Cancer Res. Front, 2, pp.1~21 (2016)
30. Low, D., "Chitinase 3-like 1 induces survival and proliferation of intestinal epithelial cells during chronic inflammation and colitis-associated cancer by regulating S100A9", Oncotarget, 6, pp.36535~36550 (2015)
31. Yu, J. E., "Anti-Chi3L1 antibody suppresses lung tumor growth and metas tasis through inhibition of M2 polarization", Mol. Oncol, 16, pp.2214~2234 (2022)
32. Ciledag, A., "High serum YKL-40 level is associated with poor prognosis in patients with lung cancer", Tuberk Toraks, 66, pp.273~279 (2018)
33. Hamilton, G., "Chitinase-3-like-1", YKL-40 as marker of circulating tumor cells, 2015, pp.4, 287~291
34. Xu, C. H., "Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer", PLoS One, 9, pp.e96384~ (2014)
35. Kim, H. R., "Levels of YKL-40 in pleural effusions and blood from patients with pulmonary or pleural disease", Cytokine, 58, pp.336~343 (2012)
36. Choi, I. K., "High serum YKL-40 is a poor prognostic marker in patients with advanced non-small cell lung cancer", Acta Oncol, 49, pp.861~864 (2010)
37. Junker, N., "Expression of YKL 40 by peritumoral macrophages in human small cell lung cancer", Lung Cancer, 48, pp.223~231 (2005)
38. Johansen, J. S., "High serum YKL-40level in patients with small cell lung cancer is related to early death", Lung Cancer, 46, pp.333~340 (2004)
39. Wang, J., "Elevated serum concentration of Chitinase 3-Like 1 is an independent prognostic biomarker for poor survival in lung cancer patients", Cell. Physiol. Biochem, 38, pp.461~468 (2016)
40. Jefri, M., "YKL-40 regulated epithelial-mesenchymal transition and migration", invasion enhancement in non small cell lung cancer, 2015, pp.15, 590~
41. Wang, X. W., "Increased expression of chitinase 3-like 1 is a prognosis marker for non-small cell lung cancer correlated with tumor angiogenesis", Tumour Biol, 36, pp.901~907 (2015)
42. Rusak, A., "The role of YKL-40 in a cancerous process", Postepy Hig. Med. Dosw, 70, pp.1286~1299 (2016)
43. Thom, I., "Elevated pretreatment serum concentration of YKL-40-An inde pendent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer", Cancer, 116, pp.4114~4121 (2010)
44. Coffman, F. D., "Chitinase 3-Like-1(CHI3L1) : a putative disease marker at the interface of proteomics and glycomics", Crit. Rev. Clin. Lab. Sci, 45, pp.531~562 (2008)
45. Johansen, J. S., "Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer", Dan Med. Bull, 53, pp.172~209 (2006)
46. Kim, D. H., "Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis", Nat. Commun, 9, pp.503~ (2018)
47. Corradi, M., "YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis", Anticancer Res, 33, pp.5517~5524 (2013)
48. Lee, C. M., "IL-13Ralpha2 uses TMEM219 in chitinase 3-like-1-induced sig nalling and effector responses", Nat. Commun, 7, pp.12752~ (2016)
49. Lee, C. G., "Role of breast regression protein 39(BRP-39)", chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis, 2009, pp.206, 1149~1166
50. Yang, P. S., "Targeting protumor factor chitinase-3-like-1 secreted by Rab37vesicles for cancer immunotherapy", Theranostics, 12, pp.340~361 (2022)
51. Ma, B., "CHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4", B7 axis, 2022, pp.13, 1056397~
52. Lee, Y. S., "A small molecule targeting CHI3L1 inhibits lung metastasis by blocking IL-13Ralpha2-mediated JNK-AP-1 signals", Mol. Oncol, 16, pp.508~526 (2022)
53. Hong, D. E., "A natural CHI3L1-targeting compound, ebractenoid F, inhibits lung cancer cell growth and migration and induces apoptosis by blocking CHI3L1", AKT signals, 2022, pp.28, 329~
54. Lauro, S., "The use of bevacizumab in non small cell lung cancer: an update", Anticancer Res, 34, pp.1537~1545 (2014)
55. Uprety, D., "Clinical utility of ramucirumab in non-small-cell lung cancer", Biologics, 13, pp.133~137 (2019)
56. Zhang, Y., "Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC", Oncol. Lett, 12, pp.3241~3249 (2016)
57. Agrawal, S., "Nivolumab dose selection : challenges, opportunities, and lessons learned for cancer immunotherapy", J. Immunother. Cancer, 4, pp.72~ (2016)
58. Low, J. L., "Low-dose pembrolizumab in the treatment of advanced non small cell lung cancer", Int. J. Cancer, 149, pp.169~176 (2021)
59. Bao, J., "Serum CHI3L1 as a biomarker for non-invasive diagnosis of liver f ibrosis", Discov. Med, 33, pp.41~49 (2022)
60. Huang, W. S., "Correlation of Chitinase 3-Like 1 single nucleotide poly morphisms with hepatocellular carcinoma in Taiwan", Int. J. Med. Sci, 14, pp.136~142 (2017)
61. Mangoud, N. O. M., "Chitinase 3-like-1, Tolloid like protein 1, and intergenic gene polymorphisms are predictors for hepato cellular carcinoma development after hepatitis C virus eradication by direct acting antivirals", IUBMB Life, 73, pp.474~482 (2021)
62. Peltonen, R., "Elevated serum YKL-40, IL-6, CRP, CEA, and CA19-9 combined as a prognostic biomarker panel after resection of colorectal liver metastases", PLoS One, 15, pp.e0236569~ (2020)
63. Wang, S., "Diagnostic and prognostic value of serum Chitinase 3-like protein 1 in hepatocellular carcinoma", J. Clin. Lab. Anal, 36, pp.e24234~ (2022)
64. Qiu, Q. C., "CHI3L1 promotes tumor progression by activating TGF-beta signaling pathway in hepatocellular carcinoma", Sci. Rep, 8, pp.15029~ (2018)
65. Lu, D., "Multi-omics profiling reveals Chitinase-3-like protein 1 as a key mediator in the crosstalk between sarcopenia and liver cancer", Redox Biol, 58, pp.102538~ (2022)
66. Shantha Kumara, H. M., "Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection", World J. Gastrointest. Oncol, 8, pp.607~614 (2016)
67. Eldaly, M. N., "Clinical potentials of miR-576-3p, miR-613, NDRG2 and YKL40 in colorectal cancer patients", Asian Pac. J. Cancer Prev, 21, pp.1689~1695 (2020)
68. Kawada, M., "Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer", Oncogene, 31, pp.3111~3123 (2012)
69. Watanabe, K., "Chitinase 3-like 1 secreted from cancer-associated fibroblasts promotes tumor angiogenesis via interleukin-8 secretion in colorectal cancer", Int. J. Oncol, 60, pp.3~ (2022)
70. Liu, K., "CHI3L1 promotes proliferation and improves sensitivity to cetuximab in colon cancer cells by down-regulating p53", J. Clin. Lab. Anal, 34, pp.e23026~ (2020)
71. Yang, M. S., "Chitinase-3-like 1(CHI3L1)gene and schizophrenia : genetic association and a potential functional mechanism", Biol. Psychiatry, 64, pp.98~103 (2008)
72. Lananna, B. V., "Chi3l1", YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer’s disease pathogenesis, 2020, pp.12, eaax3519~
73. Craig-Schapiro, R., "YKL-40 : a novel prognostic fluid biomarker for preclinical Alzheimer’s disease", Biol. Psychiatry, 68, pp.903~912 (2010)
74. Choi, J., "Plasma level of chitinase 3-like 1 protein increases in patients with early Alzheimer’s disease", J. Neurol, 258, pp.2181~2185 (2011)
75. Sanfilippo, C., "Chitinase expression in Alzheimer’s disease and non-demented brains regions", J. Neurol. Sci, 369, pp.242~249 (2016)
76. Rakic, S., "Systemic infection modifies the neuroinflammatory response in late stage Alzheimer’s disease", Acta Neuropathol. Commun, 6, pp.1~13 (2018)
77. Sanfilippo, C., "Sex-dependent neuro-deconvolution analysis of Alzheimer’s disease brain transcriptomes according to CHI3L1 expression levels", J. Neu roimmunol, 373, pp.577977~ (2022)
78. Sanfilippo, C., "CHI3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients", Mol. Cell. Neurosci, 85, pp.162~169 (2017)
79. Long, X., "Hippocampal YKL-40 expression in rats after status epilepticus", Epilepsy Res, 125, pp.52~57 (2016)
80. Carter, S. F., "Astrocyte biomarkers in Alzheimer’s disease", Trends Mol. Med, 25, pp.77~95 (2019)
81. Teitsdottir, U. D., "Cerebrospinal fluid C18 ceramide associates with markers of Alzheimer’s disease and inflammation at the pre-and early stages of dementia", J. Alzheimers Dis, 81, pp.231~244 (2021)
82. Watabe-Rudolph, M., "Chitinase enzyme activity in CSF is a powerful bio marker of Alzheimer disease", Neurology, 78, pp.569~577 (2012)
83. Groblewska, M., "YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer’s disease", Curr. Neuropharmacol, 15, pp.906~917 (2017)
84. Bonneh-Barkay, D., "Astrocyte and macrophage regulation of YKL-40expression and cellular response in neuroinflammation", Brain Pathol, 22, pp.530~546 (2012)
85. Moreno-Rodriguez, M., "Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer’s disease", J. Neuroinflamm, 17, pp.1~15 (2020)
86. Naka, K. K., "Association of vascular indices with novel circulating biomarkers as prognostic factors for cardiovascular complications in patients with type 2diabetes mellitus", Clin. Biochem, 53, pp.31~37 (2018)
87. Molina-Martínez, P., "Microglial hyperreactivity evolved to immunosup pression in the hippocampus of a mouse model of accelerated aging and Alz heimer’s Disease traits", Front. Aging Neurosci, 12, pp.622360~ (2021)
88. Chen, C. -H., "Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer’s disease", Int. J. Neuropsychopharmacol, 15, pp.77~90 (2012)
89. Rolova, T., "Deletion of nuclear factor kappa B p50 subunit decreases inflammatory response and mildly protects neurons from transient forebrain ischemia-induced damage", Aging Dis, 7, pp.450~ (2016)
90. Snow, W. M., "Neuronal gene targets of NF-κB and their dysre gulation in Alzheimer’s disease", Front. Mol. Neurosci, 9, pp.118~ (2016)
91. Gispert, J. D., "The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer’s disease but not those of sTREM2", Alzheimers Dement, 6, pp.50~59 (2017)
92. Zhang, H., "Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease", Alzheimers Dement, 7, pp.1~12 (2018)
93. Llorens, F., "YKL-40 in the brain and cerebrospinal fluid of neurodegen erative dementias", Int. J. Mol. Sci, 12, pp.1~21 (2017)
94. Jung, Y. Y., "Atherosclerosis is exacerbated by chitinase-3-like-1 in amyloid precursor protein transgenic mice", Theranostics, 8, pp.749~766 (2018)
95. Choi, J. Y., "K284-6111 prevents the amyloid beta-induced neuroin f lammation and impairment of recognition memory through inhibition of NF κB-mediated CHI3L1 expression", J. Neuroinflamm, 15, pp.1~13 (2018)
96. Ham, H. J., "K284-6111 alleviates memory impairment and neuroin f lammation in Tg2576 mice by inhibition of Chitinase-3-like 1 regulating ERK dependent PTX3 pathway", J. Neuroinflamm, 17, pp.1~16 (2020)
97. Chung, C., "Schizophrenia hippocampus has elevated expression of chondrex glycoprotein gene", Synapse, 50, pp.29~34 (2003)
98. Zhao, X., "Functional variants in the promoter region of chitinase 3–like 1(CHI3L1)and susceptibility to schizophrenia", Am. J. Hum. Genet, 80, pp.12~18 (2007)
99. Ohi, K., "The chitinase 3-like 1 gene and schizophrenia : Evidence from a multi-center case–control study and meta-analysis", Schizophr. Res, 116, pp.126~132 (2010)
100. Gomez, J. L., "Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40", J. Allergy Clin. Immunol, 136, pp.51~58 (2015)
101. Yamada, K., "Failure to confirm genetic association of the CHI3L1 gene with schizophrenia in Japanese and Chinese populations", Am. J. Med. Genet. B Neu ropsychiatr. Genet, 150, pp.508~514 (2009)
102. Kwak, E. J., "Chitinase 3-like 1 drives allergic skin inflammation via Th2immunity and M2 macrophage activation", Clin. Exp. Allergy, 49, pp.1464~1474 (2019)
103. Libreros, S., "Allergen induced pulmonary inflammation enhances mammary tumor growth and metastasis : Role of CHI3L1", J. Leukoc. Biol, 97, pp.929~940 (2015)
104. Müller, N., "Impaired monocyte activation in schizophrenia", Front. Neurosci, 198, pp.341~346 (2012)
105. Khandaker, G. M., "Is there a role for immune-to-brain commu nication in schizophrenia?", Psychopharmacology, 233, pp.1559~1573 (2016)
106. Upthegrove, R., "Cytokines, oxidative stress and cellular markers of inflammation in schizophrenia", Curr. Top Behav. Neurosci, 44, pp.49~66 (2020)
107. Emamian, E. S., "Con vergent evidence for impaired AKT1-GSK3β signaling in schizophrenia", Nat. Genet, 36, pp.131~137 (2004)
108. Zhao, T., "Chitinase-3 like-protein-1 function and its role in diseases", Signal. Transduct. Target Ther, 5, pp.201~ (2020)
109. Lencz, T., "Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia", Mol. Psychiatry, 12, pp.572~580 (2007)
110. Arion, D., "Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia", Biol. Psychiatry, 62, pp.711~721 (2007)
111. Hwang, Y., "Gene expression profiling by mRNA sequencing reveals increased expression of immune", inflammation-related genes in the hippo campus of individuals with schizophrenia, 2013, pp.3, e321~e321
112. Orhan, F., "Increased number of monocytes and plasma levels of MCP-1 and YKL-40 in first-episode psychosis", Acta Psychiatr. Scand, 138, pp.432~440 (2018)
113. Yeo, I. J., "Overexpression of transmembrane TNFalpha in brain endothelial cells induces schizophrenia-relevant behaviors", Mol. Psychiatry, 28, pp.843~855 (2023)
114. Piñero, J., "DisGeNET : a comprehensive platform integrating information on human disease-associated genes and variants", Nucleic Acids Res, 45, pp.D833~D839 (2017)
115. Hall, S., "Cerebrospinal fluid concentrations of inflammatory markers in Par kinson’s disease and atypical parkinsonian disorders", Sci. Rep, 8, pp.13276~ (2018)
116. Aarsland, D., "Parkinson disease-associated cognitive impairment", Nat. Rev. Dis. Primers, 7, pp.47~ (2021)
117. Anwar, M. M., "Early approaches of YKL-40 as a biomarker and therapeutic target for Parkinson’s disease", Neurodegener Dis. Manag, 3, pp.85~99 (2023)
118. Vu, L., "Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes", J. Neurol. Neurosurg. Psychiatry, 91, pp.350~358 (2020)
119. Vinther-Jensen, T., "Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease", Neurol. Neuroimmunol. Neuroin flamm, 3, pp.e287~ (2016)
120. Quintana, E., "Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neuro filament light chain", Eur. J. Neurol, 25, pp.1189~1191 (2018)
121. Floro, S., "Role of Chitinase 3–like 1 as a biomarker in multiple sclerosis : a systematic review and meta-analysis", Neurol. Neuroimmunol. Neuroinflamm, 9, pp.e1164~ (2022)
122. Cong, S., "Diagnostic utility of fluid biomarkers in multiple system atrophy : a systematic review and meta-analysis", J. Neurol, 268, pp.2703~2712 (2021)
123. Autar, K., "ASNTR Abstracts 2021", Cell Transplant, 30, pp.1~25 (2021)
124. Langenbruch, L., "Diagnostic utility of cere brospinal fluid(CSF)findings in seizures and epilepsy with and without autoimmune-associated disease", Seizure, 91, pp.233~243 (2021)
125. Gimbrone, M. A. Jr., "Endothelial cell dysfunction and the pathobiology of atherosclerosis", Circ. Res, 118, pp.620~636 (2016)
126. Basatemur, G. L., "Vascular smooth muscle cells in atherosclerosis", Nat. Rev. Cardiol, 16, pp.727~744 (2019)
127. Dong, Y., "Recent insights into neutrophil extracellular traps in cardiovascular diseases", J. Clin. Med, 11, pp.6662~ (2022)
128. Moroni, F., "The role of monocytes and macrophages in human atherosclerosis, plaque neoangiogen esis, and atherothrombosis", Mediators Inflamm, 2019, pp.7434376~ (2019)
129. Boot, R. G., "Strong induction of members of the chitinase family of proteins in atherosclerosis : chitotriosidase and human cartilage gp-39 expressed in lesion macrophages", Arterioscler Thromb Vasc. Biol, 19, pp.687~694 (1999)
130. Xu, T., "YKL-40 level and hypertension incidence : a population-based nested case-control study in China", J. Am. Heart Assoc, 5, pp.e004534~ (2016)
131. Malyszko, J., "YKL-40, a marker of cardiovascular disease and endothelial dysfunction, in kidney transplant recipients", Transplant Proc, 46, pp.2651~2653 (2014)
132. Erfan, G., "YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis?", Mol. Cell. Biochem, 400, pp.207~212 (2015)
133. Jafari, B., "Chitinase-3-like protein-1(YKL-40)as a marker of endothelial dysfunction in obstructive sleep apnea", Sleep Med, 25, pp.87~92 (2016)
134. Keskin, G. S., "Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease", Turk. J. Med. Sci, 49, pp.139~146 (2019)
135. Kocyigit, I., "The serum YKL-40 level is associated with vascular injury and predicts proteinuria in nephrotic syndrome patients", J. Atheroscler. Thromb, 22, pp.257~264 (2015)
136. Zheng, J. L., "Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease", Atherosclerosis, 210, pp.590~595 (2010)
137. Michelsen, A. E., "Increased YKL-40 expression in patients with carotid atherosclerosis", Atherosclerosis, 211, pp.589~595 (2010)
138. Jiao, Y., "Early identification of carotid vulnerable plaque in asymptomatic patients", BMC Cardiovasc. Disord, 20, pp.429~ (2020)
139. Wu, S., "Circulating YKL-40 level, but not CHI3L1 gene variants, is associated with atherosclerosis-related quantitative traits and the risk of peripheral artery disease", Int. J. Mol. Sci, 15, pp.22421~22437 (2014)
140. Hobaus, C., "YKL-40 levels increase with declining ankle-brachial index and are associated with long-term cardiovascular mortality in peripheral arterial disease patients", Atherosclerosis, 274, pp.152~156 (2018)
141. Aguilera, E., "Relationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population", Cardiovasc. Diabetol, 14, pp.121~ (2015)
142. Bakirci, E. M., "Serum YKL-40", chitinase 3-like protein 1 level is an inde pendent predictor of atherosclerosis development in patients with obstructive sleep apnea syndrome, 2015, pp.43, 333~339
143. Kulkarni, N. B., "Assessment of potential biomarkers of atherosclerosis in Indian patients with type 2 diabetes mellitus", Indian J. Med. Res, 147, pp.169~176 (2018)
144. Kwon, Y., "Serum YKL-40 levels are associated with the atherogenic index of plasma in children", Mediators Inflamm, 2020, pp.8713908~ (2020)
145. Yamada, K., "Serum YKL-40 level is associated with Geriatric Nutritional Risk Index(GNRI)and γ-GTP in hemodialysis patients", J. Med. Investig, 69, pp.101~106 (2022)
146. Chen, X. L., "Serum YKL-40, a prognostic marker in patients with large-artery atherosclerotic stroke", Acta Neurol. Scand, 136, pp.97~102 (2017)
147. Akboga, M. K., "Effect of serum YKL-40 on coronary collateral development and SYNTAX score in stable coronary artery disease", Int. J. Cardiol, 224, pp.323~327 (2016)
148. Sciborski, K., "Plasma YKL-40 levels correlate with the severity of coronary atherosclerosis assessed with the SYNTAX score", Pol. Arch. Intern. Med, 128, pp.644~648 (2018)
149. Schroder, J., "Prognosis and reclassification by YKL-40 in stable coronary artery disease", J. Am. Heart Assoc, 9, pp.e014634~ (2020)
150. Przybyłowski, P., "YKL-40, a novel marker of cardiovascular complications, is related to kidney function in heart transplant recipients", Transplant Proc, 46, pp.2860~2863 (2014)
151. Laucyte-Cibulskiene, A., "Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease : focus on sex-specific associations with vascular out comes and all-cause mortality", Biol. Sex Differ, 12, pp.50~ (2021)
152. Chen, G., "Elevated plasma YKL-40 as a prognostic indicator in patients with idiopathic pulmonary arterial hypertension", Respirology, 19, pp.608~615 (2014)
153. Masajtis-Zagajewska, A., "Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin resistant hypertensive patients-a randomized, crossover trial", Hypertens. Res, 33, pp.348~353 (2010)
154. Mathiasen, A. B., "Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease", Scand. J. Clin. Lab. Investig, 71, pp.439~447 (2011)
155. Qi, R., "Effect of laparoscopic splenectomy on portal vein thrombosis and serum YKL-40 in patients with cirrhotic portal hypertension", Ann. Hepatol, 18, pp.898~901 (2019)
156. Sun, X., "Chitinase 3 like 1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension", JCI Insight, 7, pp.e159578~ (2022)
157. Xing, Y., "Serum YKL-40 is associated with the severity of coronary artery disease and hypertension", Asian J. Surg, 43, pp.1121~1122 (2020)
158. Xu, T., "YKL-40 is a novel biomarker for predicting hypertension incidence among prehypertensive subjects : a population-based nested case-control study in China", Clin. Chim. Acta, 472, pp.146~150 (2017)
159. Cetin, M., "Elevated serum YKL40 level is a predictor of MACE during the long-term follow up in hypertensive patients", Clin. Exp. Hypertens, 42, pp.271~274 (2020)
160. Li, K., "Plasm YKL-40 levels are associated with hypertension in patients with obstructive sleep apnea", Biomed. Res. Int, 2019, pp.5193597~ (2019)
161. Karalilova, R., "Serum YKL-40 and IL-6 levels correlate with ultrasound f indings of articular and periarticular involvement in patients with systemic sclerosis", Rheumatol. Int, 39, pp.1841~1848 (2019)
162. Nordenbaek, C., "High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement", Scand. J. Rheumatol, 34, pp.293~297 (2005)
163. Furukawa, T., "Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis", Mod. Rheumatol, 29, pp.476~483 (2019)
164. Konig, K., "BNP, troponin I, and YKL-40 as screening markers in extremely preterm infants at risk for pulmonary hypertension associated with broncho pulmonary dysplasia", Am. J. Physiol. Lung Cell. Mol. Physiol, 311, pp.L1076~L1081 (2016)
165. Zhou, Y., "Changes in serum human cartilage glycoprotein 39 and high-mobility group box 1 in preterm infants with bronchopulmonary dysplasia", Zhongguo Dang Dai Er Ke Za Zhi, 22, pp.334~338 (2020)
166. Bilim, O., "Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure", J. Card Fail, 16, pp.873~879 (2010)
167. Ma, W. H., "Association between human cartilage glycoprotein 39(YKL-40)and arterial stiffness in essential hypertension", BMC Cardiovasc. Disord, 12, pp.35~ (2012)
168. Ma, C. Y., "Change of inflammatory factors in patients with acute coronary syndrome", Chin Med. J, 131, pp.1444~1449 (2018)
169. Harutyunyan, M., "The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure", Immunobiology, 217, pp.652~656 (2012)
170. Arain, F., "YKL-40(Chitinase-3-Like Protein 1)Serum Levels in Aortic Stenosis", Circ. Heart Fail, 13, pp.e006643~ (2020)
171. Mathiasen, A. B., "YKL-40: a new biomarker in cardiovascular disease?", Biomark. Med, 4, pp.591~600 (2010)
172. Bakirci, E. M., "New inflammatory markers for prediction of non-dipper blood pressure pattern in patients with essential hypertension : serum YKL-40", Chitinase 3-like protein 1 levels and echocardiographic epicardial adipose tissue thickness, 2015, pp.37, 505~510
173. Vergadi, E., "Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension", Circulation, 123, pp.1986~1995 (2011)
174. Waki, H., "Gene expression profiles of major cytokines in the nucleus tractus solitarii of the spontaneously hyperten sive rat", Auton. Neurosci, 142, pp.40~44 (2008)
175. Ross, R., "The pathogenesis of atherosclerosis : a perspective for the 1990s", Nature, 362, pp.801~809 (1993)
176. Libby, P., "Inflammation and atherosclerosis", Circulation, 105, pp.1135~1143 (2002)
177. Cines, D. B., "Endothelial cells in physiology and in the pathophysiology of vascular disorders", Blood, 91, pp.3527~3561 (1998)
178. Galley, H. F., "Physiology of the endothelium", Br. J. Anaesth, 93, pp.105~113 (2004)
179. Sima, A. V., "Vascular endothelium in athero sclerosis", Cell Tissue Res, 335, pp.191~203 (2009)
180. Deanfield, J. E., "Endothelial function and dysfunc tion : testing and clinical relevance", Circulation, 115, pp.1285~1295 (2007)
181. Shackelton, L. M., "Identification of a 38-kDa heparin binding glycoprotein(gp38k)in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling", J. Biol. Chem, 270, pp.13076~13083 (1995)
182. Malinda, K. M., "Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells", Exp. Cell. Res, 250, pp.168~173 (1999)
183. Jung, T. W., "Chitinase-3-like protein 1 ameliorates atherosclerotic responses via PPARδ-mediated suppression of inflammation and ER stress", J. Cell. Biochem, 119, pp.6795~6805 (2018)
184. Steenbakkers, P. G., "Localization of MHC class II", human cartilage glycoprotein-39 complexes in synovia of rheumatoid arthritis patients using complex-specific monoclonal antibodies, 2003, pp.170, 5719~5727
185. van Bilsen, J. H., "Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheuma toid arthritis", Proc. Natl. Acad. Sci. USA, 101, pp.17180~17185 (2004)
186. van Lierop, M. J., "Endogenous HLA-DR-restricted presentation of the car tilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint", Arthritis. Rheum, 56, pp.2150~2159 (2007)
187. Vos, K., "Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions", Ann. Rheum. Dis, 59, pp.544~548 (2000)
188. Tsark, E. C., "Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages", J. Immunol, 169, pp.6625~6633 (2002)
189. Vos, K., "Cellular immune response to human cartilage glycoprotein-39(HC gp-39)-derived peptides in rheumatoid arthritis and other inflammatory con ditions", Rheumatology, 39, pp.1326~1331 (2000)
190. Johansen, J. S., "A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid", Br. J. Rheumatol, 32, pp.949~955 (1993)
191. Volck, B., "Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology", Osteoarthritis Cartilage, 9, pp.203~214 (2001)
192. Baeten, D., "Detection of major histocompatibility complex", human cartilage gp-39 complexes in rheumatoid arthritis synovitis as a specific and independent histologic marker, 2004, pp.50, 444~451
193. Cope, A. P., "T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles", Arthritis Rheum, 42, pp.1497~1507 (1999)
194. Vaananen, T., "YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and inflix imab. Evidence from the randomised controlled NEO-RACo trial", PLoS One, 12, pp.e0183294~ (2017)
195. Houseman, M., "Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a long itudinal observational cohort at 8 years follow up", Arthritis Res. Ther, 14, pp.R30~ (2012)
196. Mottonen, T., "Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group", Lancet, 353, pp.1568~1573 (1999)
197. Stevens, A. L., "A sodium dodecyl sulfate-polyacrylamide gel electrophoresis-liquid chromato graphy tandem mass spectrometry analysis of bovine cartilage tissue response to mechanical compression injury and the inflammatory cytokines tumor necrosis factor alpha and interleukin-1beta", Arthritis Rheum, 58, pp.489~500 (2008)
198. Jin, T., "The Role of MicroRNA, miR-24, and Its Target CHI3L1 in Osteomyelitis Caused by Staphylococcus aureus", J. Cell. Biochem, 116, pp.2804~2813 (2015)
199. Salomon, J., "Chitinase-3Like Protein 1(YKL-40)Reflects the Severity of Symptoms in Atopic Dermatitis", J. Immunol. Res, 2017, pp.5746031~ (2017)
200. Sohn, M. H., "Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy", Am. J. Respir. Crit. Care Med, 179, pp.449~456 (2009)
201. Lee, Y. S., "New therapeutic strategy for atopic dermatitis by targeting CHI3L1", ITGA5 axis, 2022, pp.12, e739~
202. Jeon, S. H., "Inhibition of Chitinase-3-like-1 by K284-6111 Reduces Atopic Skin Inflammation via Repressing Lactoferrin", Immune Netw, 21, pp.e22~ (2021)

관련 논문AI추천